Enterosgel® in treatment of acute diarrhoea in adults
| ISRCTN | ISRCTN20758708 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN20758708 |
| Secondary identifying numbers | ENT02UK |
- Submission date
- 18/11/2016
- Registration date
- 21/11/2016
- Last edited
- 11/08/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English Summary
Background and study aims
Every year several million people in the UK suffer from intestinal infections resulting in acute (severe) diarrhoea and other symptoms (i.e. vomiting, nausea). The symptoms usually stop after a few days, but can be unpleasant. Antidiarrheal medications can slow down the bowel movements, but there is a need for treatments which could reduce the duration of diarrhoea and other symptoms and be used in both children and adults. In some European countries, intestinal adsorbents are commonly used for treating diarrhoea. One of these products is Enterosgel®, which is available over-the-counter in the UK and has been reported to remove harmful substances like bacterial toxins and allergens from the gut. However, there is limited data on its effectiveness at reducing the duration of diarrhoea and other symptoms associated with intestinal infections. The aim of this study is to collect more data about the potential benefits of using Enterosgel® in the treatment of acute diarrhoea and associated symptoms.
Who can participate?
Patients aged 18 to 70 with acute diarrhoea
What does the study involve?
Participants are randomly allocated into two groups. One group receives Enterosgel® in addition to standard rehydration treatment and the other group receive only standard rehydration treatment. The duration of the study is 1 week and involves attending one study visit at the medical practice, followed by phone calls with the research nurse every morning for the next 7 days. Participants are asked to provide a stool sample and to keep a daily diary about their symptoms and use of treatments.
What are the possible benefits and risks of participating?
It is not known whether there will be any direct benefit to the participants. However, the findings from this study can benefit the participants and other patients in the future by providing information about the effectiveness of intestinal adsorbents in the treatment of diarrhoea and associated symptoms. The patients will receive enhanced care during the study as they will speak to a healthcare professional every day. No risks are foreseen and it does not involve withholding any normal routine care procedures. The treatments used in this study are part of routine care (oral rehydration treatment) or products available over the counter and used in this study in their licensed purpose (Enterosgel).
Where is the study run from?
1. The Village Practice Thornton Medical Centre (UK)
2. West Walk Surgery (UK)
3. Pickering Medical Practice (UK)
4. Queen Square Medical Practice (UK)
5. Rowden Medical Partnership (UK)
6. Friarsgate Practice (UK)
7. Sherbourne Medical Centre (UK)
8. Cripps Health Centre (UK)
9. Chawton Park Surgery (UK)
10. Paxton Medical Group (UK)
When is the study starting and how long is it expected to run for?
September 2016 to July 2018
Who is funding the study?
Bioline Products s.r.o. (Czech Republic)
Who is the main contact?
Mrs Elena Markaryan
Contact information
Public
85 Great Portland Street, First floor
London
W1W 7LT
United Kingdom
Study information
| Study design | Randomised multi-centre post-marketing efficacy and safety study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised parallel trial |
| Study setting(s) | GP practice |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Randomised, multi-centre study to assess efficacy, tolerability and safety of Enterosgel® in treatment of acute diarrhoea in adults |
| Study hypothesis | Over-the-counter intestinal adsorbent, Enterosgel®, used together with standard of care oral rehydration treatment is more effective in the treatment of acute diarrhoea than oral rehydration treatment alone. |
| Ethics approval(s) | North West - Lancaster Research Ethics Committee, 01/12/2016, ref: 16/NW/0818 |
| Condition | Acute diarrhoea |
| Intervention | This is a 1-week randomised, multi-centre, post-marketing efficacy and safety study of a medical device used within its intended purpose. As in many medical device studies, use of placebo in this trial would be difficult. The exploratory treatment is an orally consumed organosilicon gel-like product, and similar products without any potential impact on the study outcomes and with a demonstrated safety profile would be challenging to develop. As all efficacy and safety data will be recorded in patient diaries, the study outcomes will not be subject to assessor bias. The outcomes have been defined to be as standardised as possible in order to minimise any bias resulting from the participants being unblinded. Patients will be randomised in 1:1 ratio to: 1. Control group: will receive a prescription for standard of care oral rehydration treatment (ORS) 2. Intervention group: will receive a prescription for standard of care ORS treatment together with an intestinal adsorbent, over-the-counter medical device, Enterosgel® (Bioline Products s.r.o, Czech Republic) to be taken according to study-specific dosage instructions for 5-7 days. Enterosgel study-specific dosage instructions are as follows: Day 0: First dose (as soon as possible): 2 tablespoons or 2 sachets of Enterosgel®. After the first dose: 1 tablespoon or 1 sachet of Enterosgel® after every bowel movement up to a total of 6 times and at least 3 times a day Day 1: If loose stool more than once a day: 1 tablespoon or 1 sachet of Enterosgel® after every bowel movement up to a total of 6 times and at least 3 times a day; If no loose stool or just once a day: 1 tablespoon or 1 sachet of Enterosgel® 3 times a day Days 2, 3, 4 and 5: If loose stool more than once a day: 1 tablespoon or 1 sachet of Enterosgel® 3 times a day; If no loose stool or just once a day: 1 tablespoon or 1 sachet of Enterosgel® 1-2 times a day Days 6 and 7: If loose stool more than once a day: 1 tablespoon or 1 sachet of Enterosgel® 3 times a day; If no loose stool or just once a day: Stop taking Enterosgel® Duration of the study is 1 week and will involve attending one study visit at the medical practice, followed by phone calls with the research nurse every morning for the next 7 days. The visit will involve confirmation of eligibility, informed consent and assessment of symptoms and relevant disease history. Patients will also be asked to provide a stool sample and to keep a daily diary about their symptoms and manifestations and use of treatments. A patient diary is provided to collect the data for all efficacy outcomes and serves as the source data. The diary should be filled by the patients daily and returned to the practice at the end of the study. It contains fields to record the times of bowel movements and the consistency of stools, occurrence of nausea, vomiting, body temperature in the morning and evening, abdominal pain and any other symptoms. Treatment use will also be recorded in the patient diary. Any AEs related to taking study treatment(s) should also be recorded in the patient diary. Any diarrhoea-related complications resulting in hospitalisation, Accident & Emergency department visit, nurse/GP home visit or unscheduled visit to the medical practice, should be reported by the patient during follow-up calls and recorded by the nurse in practice medical notes and the eCRF. |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | Duration of acute diarrhoea, measured using daily patient diaries throughout the study |
| Secondary outcome measures | Current secondary outcome measures as of 11/06/2018: 1. Percentage of patients with diarrhoea resolved on Day 3 (i.e. first soft or firm stool recorded on Day 0-3) 2. Stool frequency, defined as the average number of stools/day from randomisation to first soft or firm stool 3. Tolerance and safety of Enterosgel®, assessed via Adverse Event (AE) reporting from start of treatment until end of Day 7 4. Percentage of patients with diarrhoea-related complications resulting in hospitalisation, Accident & Emergency department visit, nurse/GP home visit or unscheduled visit to the medical practice from randomisation until end of Day 7 5. Duration (days) of the following from randomisation: 5.1. Nausea 5.2. Vomiting 5.3. High body temperature defined as ≥38°C 5.4. Abdominal pain All outcomes measured using daily patient diaries throughout the study Previous secondary outcome measures: 1. Percentage of patients with diarrhoea resolved on Day 3 (i.e. first soft or firm stool recorded on Day 0-3) 2. Stool frequency, defined as the average number of stools/day from first intake of treatment to first soft or firm stool 3. Tolerance and safety of Enterosgel®, assessed via Adverse Event (AE) reporting from start of treatment until end of Day 7 4. Percentage of patients with diarrhoea-related complications resulting in hospitalisation, Accident & Emergency department visit, nurse/GP home visit or unscheduled visit to the medical practice from start of treatment until end of Day 7 5. Duration (days) of the following from first intake of treatment: 5.1. Nausea 5.2. Vomiting 5.3. High body temperature defined as ≥38°C 5.4. Abdominal pain All outcomes measured using daily patient diaries throughout the study |
| Overall study start date | 01/09/2016 |
| Overall study end date | 18/07/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 104 |
| Total final enrolment | 105 |
| Participant inclusion criteria | Current inclusion criteria as of 19/05/2017: 1. Informed consent 2. Patient-reported episode of acute diarrhoea defined as at least 3 watery stools within the last 48 hours 3. Aged 18 to 70 4. Willing and able to comply with the study protocol and evaluation(s) specified in the protocol 5. Considered suitable to take part in the study by the consenting GP/nurse (based on medical history and physical examination) Previous inclusion criteria: 1. Informed consent 2. Patient-reported episode of acute diarrhoea defined as at least 3 watery stools within the last 48 hours 3. Aged 18 to 55 4. Willing and able to comply with the study protocol and evaluation(s) specified in the protocol 5. Considered suitable to take part in the study by the consenting GP (based on medical history and physical examination) |
| Participant exclusion criteria | 1. History of intestinal atony (severe constipation due to bowel obstruction) 2. Blood in stools 3. Any underlying condition that could cause chronic diarrhoea (such as gastroduodenal ulcer, ulcerative colitis, or Crohn’s disease) 4. Patients with known cancer of any localisation 5. Use of any clinical trial investigational medication within the last 30 days before screening visit 6. Use of antibiotics since the onset of current diarrhoea episode 7. Pregnancy 8. A history of clinically significant allergic reactions 9. Any underlying condition that could affect the patient’s participation in this study or the results of this study in the investigator’s opinion |
| Recruitment start date | 01/12/2016 |
| Recruitment end date | 15/12/2017 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
United Kingdom
United Kingdom
United Kingdom
United Kingdom
Chippenham
SN15 2SB
United Kingdom
Weeke
Winchester
SO22 6EL
United Kingdom
Leamington Spa
CV32 4RA
United Kingdom
Nottingham
NG7 2QW
United Kingdom
Alton
GU34 1RJ
United Kingdom
161 Park Road North
Birkenhead
CH41 0DD
United Kingdom
Sponsor information
Industry
85 Great Portland Street
First Floor
London
W1W 7LT
United Kingdom
"ROR" |
https://ror.org/013bz8f47 |
|---|
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2018 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Study results will be submitted for presentation(s) at gastroenterology conference(s) and for publication in international peer-reviewed scientific journal(s). |
| IPD sharing plan | The datasets generated and/or analysed during the current study are available from Mrs Elena Markaryan on reasonable request. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 15/04/2019 | 14/06/2019 | Yes | No |
| Protocol file | version 1.4 | 11/06/2018 | 11/08/2022 | No | Yes |
| HRA research summary | 28/06/2023 | No | No |
Additional files
Editorial Notes
11/08/2022: Uploaded protocol (not peer reviewed).
14/06/2019: The following changes were made to the trial record:
1. The overall trial end date was changed from 30/06/2018 to 18/07/2018.
2. Publication reference and total final enrolment number added.
11/06/2018: The following changes were made to the trial record:
1. Sherbourne Medical Centre, Cripps Health Centre, Chawton Park Surgery, and Paxton Medical Group were added as trial participating centres.
2. The contact/sponsor address was updated.
3. The secondary outcome measures were updated.
19/01/2018: The overall trial end date has been updated from 31/12/2017 to 30/06/2018.
19/05/2017: The following changes were made to the trial record:
1. The recruitment end date was changed from 15/03/2017 to 15/12/2017.
2. The overall trial end date was changed from 30/03/2017 to 31/12/2017.
3. Rowden Medical Partnership and Friarsgate Practice were added as trial participating centres.
